Strategies to Enhance the Efficacy of T-Cell Therapy for Central Nervous System Tumors
Mortality rates in patients diagnosed with central nervous system (CNS) tumors, originating in the brain or spinal cord, continue to remain high despite the advances in multimodal treatment regimens, including surgery, radiation, and chemotherapy. Recent success of adoptive cell transfer immunothera...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-11-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2020.599253/full |
| _version_ | 1818317955760390144 |
|---|---|
| author | Deepak Upreti Deepak Upreti David Bakhshinyan Darin Bloemberg Parvez Vora Chitra Venugopal Sheila K. Singh Sheila K. Singh Sheila K. Singh |
| author_facet | Deepak Upreti Deepak Upreti David Bakhshinyan Darin Bloemberg Parvez Vora Chitra Venugopal Sheila K. Singh Sheila K. Singh Sheila K. Singh |
| author_sort | Deepak Upreti |
| collection | DOAJ |
| description | Mortality rates in patients diagnosed with central nervous system (CNS) tumors, originating in the brain or spinal cord, continue to remain high despite the advances in multimodal treatment regimens, including surgery, radiation, and chemotherapy. Recent success of adoptive cell transfer immunotherapy treatments using chimeric antigen receptor (CAR) engineered T cells against in chemotherapy resistant CD19 expressing B-cell lymphomas, has provided the foundation for investigating efficacy of CAR T immunotherapies in the context of brain tumor. Although significant efforts have been made in developing and translating the novel CAR T therapies for CNS tumors, including glioblastoma (GBM), researchers are yet to achieve a similar level of success as with liquid malignancies. In this review, we discuss strategies and considerations essential for developing robust preclinical models for the translation of T cell-based therapies for CNS tumors. Some of the key considerations include route of delivery, increasing persistence of T cells in tumor environment, remodeling of myeloid environment, establishing the window of treatment opportunity, harnessing endogenous immune system, designing multiple antigen targeting T cells, and rational combination of immunotherapy with the current standard of care. Although this review focuses primarily on CAR T therapies for GBM, similar strategies, and considerations are applicable to all CNS tumors in general. |
| first_indexed | 2024-12-13T09:45:33Z |
| format | Article |
| id | doaj.art-998c6060224d48a096f7d3f043267a18 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-13T09:45:33Z |
| publishDate | 2020-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-998c6060224d48a096f7d3f043267a182022-12-21T23:52:04ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-11-011110.3389/fimmu.2020.599253599253Strategies to Enhance the Efficacy of T-Cell Therapy for Central Nervous System TumorsDeepak Upreti0Deepak Upreti1David Bakhshinyan2Darin Bloemberg3Parvez Vora4Chitra Venugopal5Sheila K. Singh6Sheila K. Singh7Sheila K. Singh8McMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, CanadaDepartment of Surgery, Faculty of Health Sciences, McMaster University, Hamilton, ON, CanadaMcMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, CanadaMcMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, CanadaMcMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, CanadaMcMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, CanadaMcMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, CanadaDepartment of Surgery, Faculty of Health Sciences, McMaster University, Hamilton, ON, CanadaDepartment of Biochemistry and Biomedical Sciences, Faculty of Health Sciences, McMaster University, Hamilton, ON, CanadaMortality rates in patients diagnosed with central nervous system (CNS) tumors, originating in the brain or spinal cord, continue to remain high despite the advances in multimodal treatment regimens, including surgery, radiation, and chemotherapy. Recent success of adoptive cell transfer immunotherapy treatments using chimeric antigen receptor (CAR) engineered T cells against in chemotherapy resistant CD19 expressing B-cell lymphomas, has provided the foundation for investigating efficacy of CAR T immunotherapies in the context of brain tumor. Although significant efforts have been made in developing and translating the novel CAR T therapies for CNS tumors, including glioblastoma (GBM), researchers are yet to achieve a similar level of success as with liquid malignancies. In this review, we discuss strategies and considerations essential for developing robust preclinical models for the translation of T cell-based therapies for CNS tumors. Some of the key considerations include route of delivery, increasing persistence of T cells in tumor environment, remodeling of myeloid environment, establishing the window of treatment opportunity, harnessing endogenous immune system, designing multiple antigen targeting T cells, and rational combination of immunotherapy with the current standard of care. Although this review focuses primarily on CAR T therapies for GBM, similar strategies, and considerations are applicable to all CNS tumors in general.https://www.frontiersin.org/articles/10.3389/fimmu.2020.599253/fullcentral nervous system tumorsCARTimmune systemglioblastomaT cells therapy |
| spellingShingle | Deepak Upreti Deepak Upreti David Bakhshinyan Darin Bloemberg Parvez Vora Chitra Venugopal Sheila K. Singh Sheila K. Singh Sheila K. Singh Strategies to Enhance the Efficacy of T-Cell Therapy for Central Nervous System Tumors Frontiers in Immunology central nervous system tumors CART immune system glioblastoma T cells therapy |
| title | Strategies to Enhance the Efficacy of T-Cell Therapy for Central Nervous System Tumors |
| title_full | Strategies to Enhance the Efficacy of T-Cell Therapy for Central Nervous System Tumors |
| title_fullStr | Strategies to Enhance the Efficacy of T-Cell Therapy for Central Nervous System Tumors |
| title_full_unstemmed | Strategies to Enhance the Efficacy of T-Cell Therapy for Central Nervous System Tumors |
| title_short | Strategies to Enhance the Efficacy of T-Cell Therapy for Central Nervous System Tumors |
| title_sort | strategies to enhance the efficacy of t cell therapy for central nervous system tumors |
| topic | central nervous system tumors CART immune system glioblastoma T cells therapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2020.599253/full |
| work_keys_str_mv | AT deepakupreti strategiestoenhancetheefficacyoftcelltherapyforcentralnervoussystemtumors AT deepakupreti strategiestoenhancetheefficacyoftcelltherapyforcentralnervoussystemtumors AT davidbakhshinyan strategiestoenhancetheefficacyoftcelltherapyforcentralnervoussystemtumors AT darinbloemberg strategiestoenhancetheefficacyoftcelltherapyforcentralnervoussystemtumors AT parvezvora strategiestoenhancetheefficacyoftcelltherapyforcentralnervoussystemtumors AT chitravenugopal strategiestoenhancetheefficacyoftcelltherapyforcentralnervoussystemtumors AT sheilaksingh strategiestoenhancetheefficacyoftcelltherapyforcentralnervoussystemtumors AT sheilaksingh strategiestoenhancetheefficacyoftcelltherapyforcentralnervoussystemtumors AT sheilaksingh strategiestoenhancetheefficacyoftcelltherapyforcentralnervoussystemtumors |